RU2014124984A - Конъюгаты антитело-лекарственное средство и родственные соединения, композиции и способы - Google Patents
Конъюгаты антитело-лекарственное средство и родственные соединения, композиции и способы Download PDFInfo
- Publication number
- RU2014124984A RU2014124984A RU2014124984A RU2014124984A RU2014124984A RU 2014124984 A RU2014124984 A RU 2014124984A RU 2014124984 A RU2014124984 A RU 2014124984A RU 2014124984 A RU2014124984 A RU 2014124984A RU 2014124984 A RU2014124984 A RU 2014124984A
- Authority
- RU
- Russia
- Prior art keywords
- linker
- antibody
- paragraphs
- conjugate
- formula
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 3
- 229940126601 medicinal product Drugs 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000000611 antibody drug conjugate Substances 0.000 claims abstract 18
- 229940049595 antibody-drug conjugate Drugs 0.000 claims abstract 18
- 239000002619 cytotoxin Substances 0.000 claims abstract 13
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 claims abstract 6
- 229930195731 calicheamicin Natural products 0.000 claims abstract 6
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 claims abstract 5
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 claims abstract 4
- 206010028980 Neoplasm Diseases 0.000 claims abstract 4
- 201000011510 cancer Diseases 0.000 claims abstract 4
- 229960000575 trastuzumab Drugs 0.000 claims abstract 4
- MFRNYXJJRJQHNW-DEMKXPNLSA-N (2s)-2-[[(2r,3r)-3-methoxy-3-[(2s)-1-[(3r,4s,5s)-3-methoxy-5-methyl-4-[methyl-[(2s)-3-methyl-2-[[(2s)-3-methyl-2-(methylamino)butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFRNYXJJRJQHNW-DEMKXPNLSA-N 0.000 claims abstract 3
- 101710112752 Cytotoxin Proteins 0.000 claims abstract 3
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical group CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 claims abstract 3
- 108010044540 auristatin Proteins 0.000 claims abstract 3
- 231100000599 cytotoxic agent Toxicity 0.000 claims abstract 3
- 108010093470 monomethyl auristatin E Proteins 0.000 claims abstract 3
- 108010059074 monomethylauristatin F Proteins 0.000 claims abstract 3
- 229960000548 alemtuzumab Drugs 0.000 claims abstract 2
- 239000000427 antigen Substances 0.000 claims abstract 2
- 102000036639 antigens Human genes 0.000 claims abstract 2
- 108091007433 antigens Proteins 0.000 claims abstract 2
- 125000004429 atom Chemical group 0.000 claims abstract 2
- 229960000397 bevacizumab Drugs 0.000 claims abstract 2
- 229960000455 brentuximab vedotin Drugs 0.000 claims abstract 2
- 229960005395 cetuximab Drugs 0.000 claims abstract 2
- 229960000578 gemtuzumab Drugs 0.000 claims abstract 2
- 229960002450 ofatumumab Drugs 0.000 claims abstract 2
- 229960001972 panitumumab Drugs 0.000 claims abstract 2
- 229960004641 rituximab Drugs 0.000 claims abstract 2
- 125000004434 sulfur atom Chemical group 0.000 claims abstract 2
- 229960005267 tositumomab Drugs 0.000 claims abstract 2
- 239000000562 conjugate Substances 0.000 claims 17
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 11
- 125000000217 alkyl group Chemical group 0.000 claims 9
- 229910052736 halogen Inorganic materials 0.000 claims 9
- 150000002367 halogens Chemical group 0.000 claims 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 9
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 7
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 5
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 4
- 229940125644 antibody drug Drugs 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 3
- 229910052794 bromium Inorganic materials 0.000 claims 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 2
- 239000000460 chlorine Substances 0.000 claims 2
- 125000001624 naphthyl group Chemical group 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- -1 trifluoromethanesulfonyloxy, benzenesulfonyloxy Chemical group 0.000 claims 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 1
- 229910052740 iodine Inorganic materials 0.000 claims 1
- 239000011630 iodine Substances 0.000 claims 1
- 229960005386 ipilimumab Drugs 0.000 claims 1
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 abstract 1
- WHGCQQXCXRCXJW-UZNIZVIGSA-N CC[C@H](C)[C@@H](C(N(C)[C@H](C[C@H](c1nc(C(N[C@H](C[C@H](C)C(O)=O)Cc2ccccc2)=O)c[s]1)OC(C)=O)C(C)C)=O)NC([C@@H]1NCCCC1)=O Chemical compound CC[C@H](C)[C@@H](C(N(C)[C@H](C[C@H](c1nc(C(N[C@H](C[C@H](C)C(O)=O)Cc2ccccc2)=O)c[s]1)OC(C)=O)C(C)C)=O)NC([C@@H]1NCCCC1)=O WHGCQQXCXRCXJW-UZNIZVIGSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161566909P | 2011-12-05 | 2011-12-05 | |
| US61/566,909 | 2011-12-05 | ||
| PCT/US2012/067803 WO2013085925A1 (en) | 2011-12-05 | 2012-12-04 | Antibody-drug conjugates and related compounds, compositions, and methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2014124984A true RU2014124984A (ru) | 2016-01-27 |
Family
ID=48574809
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014124984A RU2014124984A (ru) | 2011-12-05 | 2012-12-04 | Конъюгаты антитело-лекарственное средство и родственные соединения, композиции и способы |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US20130224228A1 (enExample) |
| EP (1) | EP2793585A4 (enExample) |
| JP (1) | JP2015500287A (enExample) |
| KR (1) | KR20140139480A (enExample) |
| CN (1) | CN104244718A (enExample) |
| AU (1) | AU2012348017A1 (enExample) |
| BR (1) | BR112014013526A8 (enExample) |
| CA (1) | CA2857398A1 (enExample) |
| HK (1) | HK1203309A1 (enExample) |
| IL (1) | IL232936A0 (enExample) |
| IN (1) | IN2014CN04961A (enExample) |
| MX (1) | MX2014006739A (enExample) |
| PH (1) | PH12014501229A1 (enExample) |
| RU (1) | RU2014124984A (enExample) |
| SG (1) | SG11201402686UA (enExample) |
| WO (1) | WO2013085925A1 (enExample) |
| ZA (1) | ZA201403946B (enExample) |
Families Citing this family (128)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006012527A1 (en) | 2004-07-23 | 2006-02-02 | Endocyte, Inc. | Bivalent linkers and conjugates thereof |
| EP2489372A3 (en) | 2007-03-14 | 2013-01-02 | Endocyte, Inc. | Binding ligand linked drug delivery conjugates of tubulysins |
| RU2523909C2 (ru) | 2007-06-25 | 2014-07-27 | Эндосайт, Инк. | Конъюгаты, содержащие гидрофильные спейсеры линкеров |
| US9877965B2 (en) | 2007-06-25 | 2018-01-30 | Endocyte, Inc. | Vitamin receptor drug delivery conjugates for treating inflammation |
| WO2013121175A1 (en) | 2012-02-16 | 2013-08-22 | Ucl Business Plc | Lysosome-cleavable linker |
| WO2013126797A1 (en) | 2012-02-24 | 2013-08-29 | Purdue Research Foundation | Cholecystokinin b receptor targeting for imaging and therapy |
| US20140080175A1 (en) | 2012-03-29 | 2014-03-20 | Endocyte, Inc. | Processes for preparing tubulysin derivatives and conjugates thereof |
| JP6280103B2 (ja) * | 2012-05-15 | 2018-02-14 | ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | 薬物コンジュゲート、コンジュゲーション方法およびその使用 |
| US11873281B2 (en) | 2012-07-12 | 2024-01-16 | Hangzhou Dac Biotech Co., Ltd. | Conjugates of cell binding molecules with cytotoxic agents |
| ES2781523T3 (es) | 2012-07-12 | 2020-09-02 | Hangzhou Dac Biotech Co Ltd | Conjugados de moléculas de unión celular con agentes citotóxicos |
| IN2015DN04147A (enExample) | 2012-10-16 | 2015-10-16 | Endocyte Inc | |
| ES2628156T3 (es) | 2013-02-14 | 2017-08-01 | Bristol-Myers Squibb Company | Compuestos de tubulisina, métodos para su fabricación y su uso |
| EP2968593B1 (en) | 2013-03-15 | 2024-11-20 | Regeneron Pharmaceuticals, Inc. | Biologically active molecules, conjugates thereof, and therapeutic uses |
| US20140363454A1 (en) * | 2013-06-06 | 2014-12-11 | Igenica Biotherapeutics, Inc. | Antibody-Drug Conjugates, Compositions and Methods of Use |
| WO2014197866A1 (en) | 2013-06-06 | 2014-12-11 | Igenica Biotherapeutics, Inc. | Modified antibodies and related compounds, compositions, and methods of use |
| FR3008408B1 (fr) | 2013-07-11 | 2018-03-09 | Mc Saf | Nouveaux conjugues anticorps-medicament et leur utilisation en therapie |
| MX373528B (es) | 2013-08-26 | 2020-04-21 | Regeneron Pharma | Composiciones farmacéuticas que contienen diasterómeros macrólidos, métodos para su síntesis y usos terapéuticos. |
| KR20160055253A (ko) | 2013-09-12 | 2016-05-17 | 할로자임, 아이엔씨 | 변형된 항-상피세포 성장인자 수용체 항체 및 이의 사용 방법 |
| AU2014337317A1 (en) | 2013-10-15 | 2016-09-15 | Sorrento Therapeutics Inc. | Drug-conjugates with a targeting molecule and two different drugs |
| PL3086815T3 (pl) | 2013-12-27 | 2022-06-13 | Zymeworks Inc. | Układy łącznikowe dla koniugatów leków zawierające ugrupowanie sulfonamidowe |
| EP3099681B1 (en) | 2014-01-28 | 2020-12-09 | TUBE Pharmaceuticals GmbH | Cytotoxic tubulysin compounds and conjugates thereof |
| JP2017510548A (ja) * | 2014-01-29 | 2017-04-13 | シャンハイ ヘンルイ ファーマスーティカル カンパニー リミテッドＳｈａｎｇｈａｉ Ｈｅｎｇｒｕｉ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． | リガンド‐細胞傷害性薬物抱合体、その製造方法、およびその用途 |
| GB201402009D0 (en) | 2014-02-06 | 2014-03-26 | Oncomatryx Biopharma S L | Antibody-drug conjugates and immunotoxins |
| GB201402006D0 (en) * | 2014-02-06 | 2014-03-26 | Oncomatryx Biopharma S L | Antibody-drug conjugates and immunotoxins |
| JP2017506640A (ja) | 2014-02-14 | 2017-03-09 | セントローズ， エルエルシー | 細胞外標的化薬物共役体 |
| RS59077B1 (sr) | 2014-03-11 | 2019-09-30 | Regeneron Pharma | Anti-egfrviii antitela i njihova primena |
| SG11201608203RA (en) * | 2014-04-11 | 2016-10-28 | Medimmune Llc | Tubulysin derivatives |
| HK1231367A1 (zh) | 2014-06-02 | 2017-12-22 | Regeneron Pharmaceuticals, Inc. | 抗体药物偶联物、试剂和制备方法及其治疗用途 |
| MY191346A (en) | 2014-06-03 | 2022-06-17 | Xbiotech Inc | Compositions and methods for treating and preventing staphylococcus aureus infections |
| AU2015315007C1 (en) | 2014-09-11 | 2021-06-03 | Seagen Inc. | Targeted delivery of tertiary amine-containing drug substances |
| CN108064282A (zh) | 2014-10-14 | 2018-05-22 | 哈洛齐梅公司 | 腺苷脱氨酶-2(ada2)、其变体的组合物及使用其的方法 |
| EP3209334A2 (en) * | 2014-10-20 | 2017-08-30 | Igenica Biotherapeutics, Inc. | Novel antibody-drug conjugates and related compounds, compositions, and methods of use |
| AU2015339012B2 (en) | 2014-10-31 | 2020-11-05 | Abbvie Biotherapeutics Inc. | Anti-CS1 antibodies and antibody drug conjugates |
| US10556959B2 (en) | 2014-11-07 | 2020-02-11 | Xencor, Inc. | Anti-CD39 antibodies and uses thereof |
| US10077287B2 (en) * | 2014-11-10 | 2018-09-18 | Bristol-Myers Squibb Company | Tubulysin analogs and methods of making and use |
| BR112017012377A2 (pt) | 2014-12-09 | 2018-04-24 | Abbvie Inc | conjugados anticorpo-fármaco com inibidores de bcl-xl permeáveis à célula |
| EP3230282A1 (en) | 2014-12-09 | 2017-10-18 | AbbVie Inc. | Bcl xl inhibitory compounds having low cell permeability and antibody drug conjugates including the same |
| EP3230283A1 (en) | 2014-12-09 | 2017-10-18 | AbbVie Inc. | Bcl-xl inhibitory compounds and antibody drug conjugates including the same |
| JP6676058B2 (ja) | 2015-01-14 | 2020-04-08 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ヘテロアリーレン架橋したベンゾジアゼピン二量体、そのコンジュゲート、ならびに製造および使用方法 |
| EP4137159A1 (en) | 2015-01-28 | 2023-02-22 | Sorrento Therapeutics, Inc. | Antibody drug conjugates |
| WO2016144608A1 (en) * | 2015-03-10 | 2016-09-15 | Bristol-Myers Squibb Company | Antibodies conjugatable by transglutaminase and conjugates made therefrom |
| SG11201707148PA (en) | 2015-03-27 | 2017-10-30 | Regeneron Pharma | Maytansinoid derivatives, conjugates thereof, and methods of use |
| WO2016165762A1 (en) * | 2015-04-15 | 2016-10-20 | Ganymed Pharmaceuticals Ag | Drug conjugates comprising antibodies against claudin 18.2 |
| CN106279352B (zh) | 2015-05-29 | 2020-05-22 | 上海新理念生物医药科技有限公司 | 海兔毒素10的衍生物及其应用 |
| CN106267225B (zh) | 2015-05-29 | 2020-03-06 | 上海新理念生物医药科技有限公司 | 三马来酰亚胺型连接子及其应用 |
| EP3319994B1 (en) | 2015-07-06 | 2024-02-07 | Regeneron Pharmaceuticals, Inc. | Multispecific antigen-binding molecules and uses thereof |
| JP7330515B2 (ja) * | 2015-08-10 | 2023-08-22 | ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ． | 新規な連結体及び生体分子と薬物との特異的共役におけるその使用 |
| CN115300640A (zh) * | 2015-08-10 | 2022-11-08 | 杭州多禧生物科技有限公司 | 新型连接体及其用于药物和生物分子的特异性偶联 |
| DK3334462T3 (da) * | 2015-08-14 | 2022-02-14 | Rc Biotechnologies Inc | Kovalente linkere i antistof-lægemiddel-konjugater og fremgangsmåder til fremstilling og anvendelse deraf |
| CN114814055B (zh) * | 2015-09-08 | 2025-03-18 | 沃特世科技公司 | 用于分析抗体-药物缀合物的多维色谱方法 |
| EP3383909B1 (en) | 2015-11-30 | 2020-06-17 | AbbVie Inc. | Anti-human lrrc15 antibody drug conjugates and methods for their use |
| US10195209B2 (en) | 2015-11-30 | 2019-02-05 | Abbvie Inc. | Anti-huLRRC15 antibody drug conjugates and methods for their use |
| US11229708B2 (en) * | 2015-12-04 | 2022-01-25 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
| US11793880B2 (en) | 2015-12-04 | 2023-10-24 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
| IL259864B (en) | 2015-12-09 | 2022-07-01 | Univ Wien Med | Monomaleimide-functionalized platinum compounds for cancer therapy |
| EP3387017A1 (en) | 2015-12-11 | 2018-10-17 | Regeneron Pharmaceuticals, Inc. | Methods for reducing or preventing growth of tumors resistant to egfr and/or erbb3 blockade |
| CN108779127B (zh) | 2016-01-25 | 2022-07-05 | 里珍纳龙药品有限公司 | 美登素类化合物衍生物、其偶联物和使用方法 |
| US20190365913A1 (en) * | 2016-02-04 | 2019-12-05 | Tarveda Therapeutics, Inc. | Stapled peptide conjugates and particles |
| WO2017161206A1 (en) | 2016-03-16 | 2017-09-21 | Halozyme, Inc. | Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use |
| MA45328A (fr) | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | Compositions acide nucléique-polypeptide et utilisations de celles-ci |
| US11352446B2 (en) | 2016-04-28 | 2022-06-07 | Regeneron Pharmaceuticals, Inc. | Methods of making multispecific antigen-binding molecules |
| RU2740996C2 (ru) | 2016-05-17 | 2021-01-22 | Эббви Байотерапьютикс Инк. | КОНЪЮГАТЫ АНТИТЕЛА К cMet И ЛЕКАРСТВЕННОГО СРЕДСТВА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
| US10640563B2 (en) | 2016-06-08 | 2020-05-05 | Abbvie Inc. | Anti-B7-H3 antibodies and antibody drug conjugates |
| CN109562168A (zh) | 2016-06-08 | 2019-04-02 | 艾伯维公司 | 抗cd98抗体及抗体药物偶联物 |
| MX2018015274A (es) | 2016-06-08 | 2019-10-07 | Abbvie Inc | Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco. |
| US20190153107A1 (en) | 2016-06-08 | 2019-05-23 | Abbvie Inc. | Anti-egfr antibody drug conjugates |
| AU2017279554A1 (en) | 2016-06-08 | 2019-01-03 | Abbvie Inc. | Anti-B7-H3 antibodies and antibody drug conjugates |
| EP3468616A1 (en) | 2016-06-08 | 2019-04-17 | AbbVie Inc. | Anti-egfr antibody drug conjugates |
| JP2019526529A (ja) | 2016-06-08 | 2019-09-19 | アッヴィ・インコーポレイテッド | 抗ｂ７−ｈ３抗体及び抗体薬物コンジュゲート |
| CA3027047A1 (en) | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-cd98 antibodies and antibody drug conjugates |
| CN116059202A (zh) | 2016-06-08 | 2023-05-05 | 艾伯维公司 | 抗egfr抗体药物偶联物 |
| US20190328900A1 (en) | 2016-07-01 | 2019-10-31 | Glaxosmithkline Intellectual Property Development Limited | Antibody-drug conjugates and therapeutic methods using the same |
| CN109562152B (zh) | 2016-08-09 | 2024-04-02 | 西雅图基因公司 | 含有具有改善的生理化学性质的自稳定性接头的药物缀合物 |
| EP3515487B1 (en) | 2016-09-23 | 2023-07-19 | Regeneron Pharmaceuticals, Inc. | Bi specific anti-muc16-cd3 antibodies and anti-muc16 drug conjugates |
| JP7078609B2 (ja) | 2016-09-23 | 2022-05-31 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗ｓｔｅａｐ２抗体、抗体－薬物複合体、およびｓｔｅａｐ２とｃｄ３を結合する二重特異性抗原結合分子、ならびにそれらの使用 |
| JP7330101B2 (ja) | 2016-11-08 | 2023-08-21 | レゲネロン ファーマシューティカルス，インコーポレーテッド | ステロイド及びそのタンパク質コンジュゲート |
| TWI782930B (zh) | 2016-11-16 | 2022-11-11 | 美商再生元醫藥公司 | 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法 |
| CN109810039B (zh) * | 2017-11-22 | 2021-11-12 | 迈威(上海)生物科技股份有限公司 | 一种用于抗体-药物偶联的双取代马来酰胺类连接子及其制备方法和用途 |
| US10864279B2 (en) | 2016-12-16 | 2020-12-15 | Industrial Technology Research Institute | Linker-drug and antibody-drug conjugate (ADC) employing the same |
| MX2019011957A (es) * | 2017-04-06 | 2019-11-07 | Hangzhou Dac Biotech Co Ltd | Conjugacion de un farmaco citotoxico con enlace bis. |
| US11491237B2 (en) | 2017-05-18 | 2022-11-08 | Regeneron Pharmaceuticals, Inc. | Cyclodextrin protein drug conjugates |
| CA3066569A1 (en) | 2017-06-07 | 2018-12-13 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for internalizing enzymes |
| CN107652219B (zh) | 2017-08-14 | 2021-06-08 | 上海新理念生物医药科技有限公司 | 四马来酰亚胺型连接子及其应用 |
| CN111788208B (zh) * | 2017-09-20 | 2023-11-24 | Ph制药有限公司 | 泰兰他汀类似物 |
| MX2020004691A (es) | 2017-11-07 | 2020-08-20 | Regeneron Pharma | Enlazadores hidrofilicos para conjugados anticuerpo-farmaco. |
| BR112020013492A2 (pt) | 2018-01-08 | 2020-12-08 | Regeneron Pharmaceuticals, Inc. | Esteroides e conjugados de anticorpo dos mesmos |
| AU2019262953B2 (en) | 2018-04-30 | 2025-12-04 | Regeneron Pharmaceuticals, Inc. | Antibodies, and bispecific antigen-binding molecules that bind HER2 and/or APLP2, conjugates, and uses thereof |
| KR20210008008A (ko) | 2018-05-09 | 2021-01-20 | 리제너론 파마슈티칼스 인코포레이티드 | 항-msr1 항체 및 이의 사용 방법 |
| CA3100021A1 (en) | 2018-05-17 | 2019-11-21 | Regeneron Pharmaceuticals, Inc. | Anti-cd63 antibodies, conjugates, and uses thereof |
| UY38251A (es) | 2018-06-01 | 2019-12-31 | Novartis Ag | Moléculas de unión contra bcma y usos de las mismas |
| CN109602915A (zh) * | 2018-07-03 | 2019-04-12 | 烟台迈百瑞国际生物医药有限公司 | 抗体-t2毒素缀合物及其用途 |
| IL321689A (en) | 2018-07-26 | 2025-08-01 | Curevac Netherlands B V | Vaccines against breast cancer |
| EP3827264A1 (en) | 2018-07-26 | 2021-06-02 | Frame Pharmaceuticals B.V. | Arid1a, cdkn2a, kmt2b, kmt2d, tp53 and pten vaccines for cancer |
| WO2020022902A1 (en) | 2018-07-26 | 2020-01-30 | Frame Pharmaceuticals B.V. | Cancer vaccines for colorectal cancer |
| WO2020022900A1 (en) | 2018-07-26 | 2020-01-30 | Frame Pharmaceuticals B.V. | Cancer vaccines for kidney cancer |
| IL321690A (en) | 2018-07-26 | 2025-08-01 | Curevac Netherlands B V | Cancer vaccines for uterine cancer |
| KR20210083282A (ko) * | 2018-12-17 | 2021-07-06 | 레메젠 코, 리미티드 | 항체-약물 컨쥬게이트에 사용하기 위한 커넥터 및 커넥터의 적용 |
| IL318210A (en) | 2018-12-21 | 2025-03-01 | Regeneron Pharma | Rifampicin analogs and their antibody-drug conjugates |
| IL319265A (en) | 2018-12-21 | 2025-04-01 | Avidity Biosciences Inc | Anti-transferrin receptor antibodies and their uses |
| CN113727757A (zh) | 2019-02-21 | 2021-11-30 | 瑞泽恩制药公司 | 使用结合met的抗-met抗体和双特异性抗原结合分子治疗眼癌的方法 |
| TWI877186B (zh) | 2019-07-19 | 2025-03-21 | 美商免疫感應治療公司 | 抗體-干擾素基因刺激蛋白(sting)促效劑結合物及其於免疫療法之用途 |
| JP7303298B2 (ja) | 2019-08-07 | 2023-07-04 | 煙台邁百瑞国際生物医薬股▲ふん▼有限公司 | 抗体薬物複合体及びその応用 |
| MX2022002886A (es) | 2019-09-16 | 2022-04-06 | Regeneron Pharma | Proteinas de union met radiomarcadas para la obtencion de imagenes por inmuno-pet. |
| US11814428B2 (en) | 2019-09-19 | 2023-11-14 | Regeneron Pharmaceuticals, Inc. | Anti-PTCRA antibody-drug conjugates and uses thereof |
| IL295312A (en) | 2020-02-28 | 2022-10-01 | Regeneron Pharma | Bispecific antigen binding molecules that bind her2, and methods of use thereof |
| US20230126689A1 (en) | 2020-03-06 | 2023-04-27 | Go Therapeutics, Inc. | Anti-glyco-cd44 antibodies and their uses |
| IL296387B2 (en) | 2020-03-19 | 2024-08-01 | Avidity Biosciences Inc | Preparations and methods for the treatment of facial, back and arm muscle atrophy |
| MX2022011880A (es) | 2020-03-27 | 2022-10-20 | Avidity Biosciences Inc | Composiciones y metodos para tratar distrofia muscular. |
| IL297027B2 (en) | 2020-04-16 | 2025-08-01 | Regeneron Pharma | Antibody-drug conjugates prepared using diels-alder conjugation methods |
| CA3183184A1 (en) | 2020-07-13 | 2022-01-20 | Regeneron Pharmaceuticals, Inc. | Camptothecin analogs conjugated to a glutamine residue in a protein, and their use |
| KR20230070337A (ko) | 2020-09-14 | 2023-05-22 | 리제너론 파마슈티칼스 인코포레이티드 | Glp1 펩티도미메틱을 포함하는 항체-약물 접합체 및 이의 용도 |
| MX2023004434A (es) | 2020-10-22 | 2023-05-08 | Regeneron Pharma | Anticuerpos anti-fgfr2 y metodos para usarlos. |
| UY39610A (es) | 2021-01-20 | 2022-08-31 | Abbvie Inc | Conjugados anticuerpo-fármaco anti-egfr |
| WO2022187591A1 (en) | 2021-03-05 | 2022-09-09 | Go Therapeutics, Inc. | Anti-glyco-cd44 antibodies and their uses |
| JP2024531915A (ja) | 2021-08-05 | 2024-09-03 | ジーオー セラピューティクス，インコーポレイテッド | 抗グリコｍｕｃ抗体およびその使用 |
| US11807685B2 (en) * | 2021-08-05 | 2023-11-07 | The Uab Research Foundation | Anti-CD47 antibody and uses thereof |
| CA3230933A1 (en) | 2021-09-03 | 2023-03-09 | Go Therapeutics, Inc. | Anti-glyco-lamp1 antibodies and their uses |
| AU2022339667A1 (en) | 2021-09-03 | 2024-04-11 | Go Therapeutics, Inc. | Anti-glyco-cmet antibodies and their uses |
| KR20240055874A (ko) | 2021-09-16 | 2024-04-29 | 어비디티 바이오사이언시스 인크. | 안면견갑상완 근이영양증을 치료하는 조성물 및 방법 |
| JP2025502147A (ja) | 2022-01-12 | 2025-01-24 | リジェネロン ファーマシューティカルズ，インク． | タンパク質中のグルタミン残基にコンジュゲートしたカンプトテシンアナログおよびその使用 |
| JP2025512735A (ja) | 2022-03-11 | 2025-04-22 | リジェネロン ファーマシューティカルズ，インク． | Ｇｌｐ１ペプチド模倣体を含む抗ｇｌｐ１ｒ抗体係留型薬物コンジュゲートおよびその使用 |
| AU2023310999A1 (en) | 2022-07-21 | 2025-01-23 | Firefly Bio, Inc. | Glucocorticoid receptor agonists and conjugates thereof |
| CN115814111B (zh) * | 2022-12-05 | 2025-03-28 | 复旦大学附属中山医院 | 一种近红外荧光adc免疫制剂及其制备方法与应用 |
| KR20250133813A (ko) | 2022-12-21 | 2025-09-08 | 리제너론 파마슈티칼스 인코포레이티드 | Adc 접합을 위한 토포이소머라아제 i 억제제의 전구약물 및 이의 사용 방법 |
| WO2024229105A1 (en) | 2023-05-02 | 2024-11-07 | Regeneron Pharmaceuticals, Inc. | Anti-human m-cadherin (cdh15) antibodies, conjugates, and uses thereof for delivery of genetic payloads to muscle cells |
| WO2025014533A1 (en) | 2023-07-10 | 2025-01-16 | Regeneron Pharmaceuticals, Inc. | Anti-human cacng1 antibody-drug conjugates and uses thereof |
| WO2025096921A1 (en) | 2023-11-03 | 2025-05-08 | Regeneron Pharmaceuticals, Inc. | Peptide acids as a glp1r agonist and antibody-drug conjugates thereof |
| WO2025114426A1 (en) | 2023-11-28 | 2025-06-05 | Universite De Strasbourg | Preparation of protein conjugates via one-pot multicomponent reaction |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2211443A1 (en) * | 1995-01-26 | 1996-08-01 | Biogen, Inc. | Lymphotoxin-.alpha./.beta. complexes and anti-lymphotoxin-beta receptor antibodies as anti-tumor agents |
| ES2369542T3 (es) * | 2002-07-31 | 2011-12-01 | Seattle Genetics, Inc. | Conjugados de auristatina y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa. |
| DE10254439A1 (de) * | 2002-11-21 | 2004-06-03 | GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) | Tubulysine, Herstellungsverfahren und Tubulysin-Mittel |
| ES2456325T3 (es) * | 2003-11-06 | 2014-04-22 | Seattle Genetics, Inc. | Compuestos de monometilvalina capaces de conjugación con ligandos |
| US7740861B2 (en) * | 2004-06-16 | 2010-06-22 | University Of Massachusetts | Drug delivery product and methods |
| BRPI0516284A (pt) * | 2004-09-23 | 2008-09-02 | Genentech Inc | anticorpo construìdo com cisteìna, método de selecionar anticorpos, compostos conjugados de droga-anticorpo, composição farmacêutica, método para matar ou inibir a proliferação de células de tumor, métodos de inibir a proliferação celular e o crescimento de células de tumor, artigo manufaturado e método para produzir um composto |
| CA2623293A1 (en) * | 2005-09-20 | 2007-03-29 | Shimon Benita | Nanoparticles for targeted delivery of active agents |
| AR069747A1 (es) * | 2007-11-30 | 2010-02-17 | Medarex Inc | Conjugado anticuerpo monoclonal anti-b7h4- farmaco y metodos de utilizacion |
| JP2011524421A (ja) * | 2008-06-16 | 2011-09-01 | イミュノジェン・インコーポレーテッド | 新規の相乗効果 |
| WO2010009124A2 (en) * | 2008-07-15 | 2010-01-21 | Genentech, Inc. | Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds |
| CA2770617C (en) * | 2009-08-10 | 2018-02-20 | Mark Smith | Reversible covalent linkage of functional molecules |
| EP2822597A1 (en) * | 2012-03-09 | 2015-01-14 | UCL Business Plc. | Chemical modification of antibodies |
-
2012
- 2012-12-04 IN IN4961CHN2014 patent/IN2014CN04961A/en unknown
- 2012-12-04 MX MX2014006739A patent/MX2014006739A/es unknown
- 2012-12-04 JP JP2014546004A patent/JP2015500287A/ja active Pending
- 2012-12-04 HK HK15104134.2A patent/HK1203309A1/xx unknown
- 2012-12-04 WO PCT/US2012/067803 patent/WO2013085925A1/en not_active Ceased
- 2012-12-04 US US13/705,074 patent/US20130224228A1/en not_active Abandoned
- 2012-12-04 KR KR1020147018663A patent/KR20140139480A/ko not_active Withdrawn
- 2012-12-04 SG SG11201402686UA patent/SG11201402686UA/en unknown
- 2012-12-04 CA CA2857398A patent/CA2857398A1/en not_active Abandoned
- 2012-12-04 EP EP12855849.1A patent/EP2793585A4/en not_active Withdrawn
- 2012-12-04 BR BR112014013526A patent/BR112014013526A8/pt not_active Application Discontinuation
- 2012-12-04 RU RU2014124984A patent/RU2014124984A/ru not_active Application Discontinuation
- 2012-12-04 AU AU2012348017A patent/AU2012348017A1/en not_active Abandoned
- 2012-12-04 CN CN201280067454.XA patent/CN104244718A/zh active Pending
-
2014
- 2014-05-29 ZA ZA2014/03946A patent/ZA201403946B/en unknown
- 2014-05-30 PH PH12014501229A patent/PH12014501229A1/en unknown
- 2014-06-02 IL IL232936A patent/IL232936A0/en unknown
-
2015
- 2015-08-24 US US14/834,078 patent/US20160303247A1/en not_active Abandoned
-
2019
- 2019-12-27 US US16/728,045 patent/US20200392108A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| PH12014501229A1 (en) | 2014-09-08 |
| BR112014013526A2 (pt) | 2017-06-13 |
| US20160303247A1 (en) | 2016-10-20 |
| CN104244718A (zh) | 2014-12-24 |
| US20200392108A1 (en) | 2020-12-17 |
| IN2014CN04961A (enExample) | 2015-09-18 |
| AU2012348017A1 (en) | 2014-07-03 |
| HK1203309A1 (zh) | 2015-10-30 |
| US20130224228A1 (en) | 2013-08-29 |
| EP2793585A1 (en) | 2014-10-29 |
| CA2857398A1 (en) | 2013-06-13 |
| BR112014013526A8 (pt) | 2017-06-13 |
| JP2015500287A (ja) | 2015-01-05 |
| KR20140139480A (ko) | 2014-12-05 |
| ZA201403946B (en) | 2015-09-30 |
| WO2013085925A1 (en) | 2013-06-13 |
| MX2014006739A (es) | 2015-06-05 |
| SG11201402686UA (en) | 2014-06-27 |
| IL232936A0 (en) | 2014-07-31 |
| EP2793585A4 (en) | 2015-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2014124984A (ru) | Конъюгаты антитело-лекарственное средство и родственные соединения, композиции и способы | |
| JP7254861B2 (ja) | エリブリンをベースとする抗体－薬物コンジュゲート及び使用方法 | |
| JP2019532056A5 (enExample) | ||
| RU2487877C2 (ru) | Высокоэффективные конъюгаты и гидрофильные сшивающие агенты (линкеры) | |
| JP2023089195A (ja) | グリピカン３抗体およびそのコンジュゲート | |
| JP7695260B2 (ja) | Ｈｅｒ２に結合する二重特異性抗原結合分子およびその使用方法 | |
| JP2019536740A5 (enExample) | ||
| RU2014146951A (ru) | Конъюгаты типа лиганд dr5-лекарственное средство | |
| RU2016133846A (ru) | Конъюгат лиганд - цитотоксическое лекарственное средство, способ его получения и его применения | |
| RU2015119561A (ru) | Новые конъюгаты лекарственное вещество-белок | |
| JP2016523810A5 (enExample) | ||
| RU2015119557A (ru) | Конъюгаты лекарственное вещество-белок | |
| EA200600275A1 (ru) | Цитотоксический конъюгат, специфичный по отношению к са6 антигену, и способы его применения | |
| WO2021207701A1 (en) | Charge variant linkers | |
| PE20120899A1 (es) | Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b | |
| RU2016139340A (ru) | Коньюгаты "антитело - лекарственное средство" с высокой лекарственной нагрузкой | |
| EA035374B1 (ru) | Антитела против cd48 и их конъюгаты | |
| MX2020011554A (es) | Composiciones y metodos relacionados con conjugados de farmacos de anticuerpo anti grupo de diferenciacion 19 (cd19). | |
| RU2016129894A (ru) | Ковалентно связанные конъюгаты хеликар-антитело против хеликара и их применения | |
| RU2009110102A (ru) | Лечение опухолей с помощью антитела к vegf | |
| MY153893A (en) | Antibodies against human il17 and uses thereof | |
| RU2014128467A (ru) | Новые коньюгаты связывающее соединение-активное соединение (adc) и их применение | |
| EA201000910A1 (ru) | Конъюгат "моноклональное антитело против в7н4/лекарственное средство" и способы его применения | |
| RU2013151599A (ru) | Новые конъюгаты связывающее соединение-активное соединение (adc) и их применение | |
| EP2570137A3 (en) | Antibodies that bind human dendritic and epithelial cell 205 (DEC-205) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20170721 |